Genzyme
E561775
Genzyme is a biotechnology company best known for developing treatments for rare genetic disorders and other specialty diseases.
Statements (48)
| Predicate | Object |
|---|---|
| instanceOf | biotechnology company ⓘ |
| acquiredBy | Sanofi NERFINISHED ⓘ |
| acquisitionDate | 2011 ⓘ |
| acquisitionValue | 20100000000 USD ⓘ |
| country |
United States of America
ⓘ
surface form:
United States
|
| developsTreatmentFor |
Fabry disease
ⓘ
Gaucher disease NERFINISHED ⓘ Pompe disease NERFINISHED ⓘ chronic kidney disease ⓘ multiple sclerosis ⓘ |
| dissolvedAsIndependentCompany | 2011 ⓘ |
| focusesOn |
endocrinology
ⓘ
genetic disorders ⓘ lysosomal storage disorders ⓘ multiple sclerosis ⓘ oncology ⓘ rare diseases ⓘ renal disease ⓘ |
| formerName | Genzyme Corporation NERFINISHED ⓘ |
| foundedBy |
Alex Grass
NERFINISHED
ⓘ
George M. Whitesides NERFINISHED ⓘ Henry Blair NERFINISHED ⓘ James Cavanaugh NERFINISHED ⓘ Sheridan Snyder NERFINISHED ⓘ |
| hasProduct |
Aubagio
NERFINISHED
ⓘ
Cerezyme NERFINISHED ⓘ Fabrazyme NERFINISHED ⓘ Lemtrada NERFINISHED ⓘ Lumizyme NERFINISHED ⓘ Myozyme NERFINISHED ⓘ Renagel NERFINISHED ⓘ Renvela NERFINISHED ⓘ Thymoglobulin NERFINISHED ⓘ |
| headquartersLocation | Cambridge, Massachusetts NERFINISHED ⓘ |
| inception | 1981 ⓘ |
| industry |
biotechnology
ⓘ
pharmaceuticals ⓘ |
| locatedIn | Massachusetts ⓘ |
| numberOfEmployees | approximately 10000 ⓘ |
| operatesIn |
Asia
ⓘ
Europe ⓘ North America ⓘ |
| parentOrganization | Sanofi NERFINISHED ⓘ |
| specializesIn |
enzyme replacement therapy
ⓘ
orphan drugs ⓘ |
| stockExchangeListing | formerly NASDAQ:GENZ ⓘ |
| subsidiaryOf | Sanofi NERFINISHED ⓘ |
| website | https://www.sanofigenzyme.com ⓘ |
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.